Skip to main content
. Author manuscript; available in PMC: 2022 Sep 27.
Published in final edited form as: Biostat Epidemiol. 2021 Sep 27;5(2):267–286. doi: 10.1080/24709360.2021.1975255

Table 4:

Power and medical costs using AWA in hypothesis testing.

Scenario Prevalence Range Relative Importance Power Medical Cost
Diagnostic vs Best Random Test 5%−10% 0.1 0.627 66
5%−10% 0.25 0.072 75
10%−30% 0.1 0.126 79
10%−30% 0.25 0.998 161
Independent sample: Diagnostic 1 vs Diagnostic 2 5%−10% 0.1 0.455 63
5%−10% 0.25 0.294 74
10%−30% 0.1 0.474 78
10%−30% 0.25 0.742 153
One sample: Diagnostic 1 vs Diagnostic 2 5%−10% 0.1 0.738 63
5%−10% 0.25 0.491 74
10%−30% 0.1 0.74 78
10%−30% 0.25 0.959 153